Most Recent
Hungry Jack’s wants 5 years of Big Mac sales data in spat over damages for misleading ads
Hungry Jack’s is seeking five years of Big Mac sales data as it readies for a fight over damages stemming from its claim that its Big Jack burger has 25 per cent more beef than the McDonald's burger.
Zoetis can appeal Boehringer win over pig vaccine patents
US animal drug manufacturer Zoetis has been granted leave to appeal a ruling that invalidated three of its patents covering pig vaccines.
In trade mark appeal, Katy Perry says Aussie designer should have ‘changed direction’ given her rise to fame
Appealing her loss in a trade mark stoush with an Australian fashion designer, pop star Katy Perry has argued the woman “should have changed direction” with her ‘Katie Perry’ brand once the singer's star began to rise. 
Samsung Bioepis sues Janssen Biotech to invalidate Stelara patents
South Korean biosimilars company Samsung Bioepis has sued Johnson & Johnson's Janssen Biotech to invalidate two patents for Crohn's disease drug Stelara, after reaching a licencing agreement over the medicine in the US.
‘Harry is not Barry’: McDonald’s loses trade mark case against Hungry Jack’s
A judge has rejected McDonald's claim that Hungry Jack's Big Jack burger infringed its Big Mac trade mark, but found that Hungry Jack's misled consumers by boasting that its burger had 25 per cent more beef.
Bayer defeats Sandoz challenge to patents for blood thinner Xarelto
Novartis unit Sandoz AG has lost its bid to revoke Bayer’s patents for its top-selling blood clot drug Xarelto and has been barred from selling generic versions of the medication after a judge found the German pharma giant’s patents were valid.
Court hands win to Boehringer in fight over Zoetis vaccine patents
German drug maker Boehringer has prevailed in its Federal Court fight against US rival Zoetis over the validity of three patents covering pig vaccines.
Lights out on Hanhwa’s solar cell patent infringement suit
A solar cell patent at the heart of intellectual property litigation brought by South Korean technology giant Hanwha has been found invalid.
Federal Court rejects ToolGen’s genome editing patent
A judge has upheld findings from IP Australia that South Korean biotech ToolGen's genome editing technology CRISPR is not patentable, but given the company one more chance to seek to amend its application.
Lundbeck’s decade-long damages bid against Sandoz stayed despite High Court win
Novartis unit Sandoz has won its bid to stay a case by rival Lundbeck, including orders for damages previously calculated at $26.3 million and counting, despite having succeeded at the High Court in a dispute over its patent for blockbuster antidepressant Lexapro.